Neurology

Real-world outcomes with investigational drug still favourable

The new drug safinamide might have some impact in preventing the involuntary movements characteristic of Parkinson's disease. However, it did not perform any better than placebo over a two-year period.

New treatment is effective in Canada and U.S., but not in rest of North America; epilepsy classification may have been a factor

Course improves memory by recruiting healthy tissue

Prototype is portable, easy to use

Research from Australia—which has the highest skin cancer rate in the world—suggests sun exposure also can be viewed in a sort of positive light: It may reduce the risk for developing multiple sclerosis.